.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

ARESTIN Drug Profile

« Back to Dashboard
Arestin is a drug marketed by Orapharma and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

This drug has twelve patent family members in twelve countries.

The generic ingredient in ARESTIN is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for Tradename: ARESTIN

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Pharmacology for Tradename: ARESTIN

Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug

Clinical Trials for: ARESTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orapharma
ARESTIN
minocycline hydrochloride
POWDER, EXTENDED RELEASE;DENTAL050781-001Feb 16, 2001RXYes7,699,609<disabled>Y <disabled>
Orapharma
ARESTIN
minocycline hydrochloride
POWDER, EXTENDED RELEASE;DENTAL050781-001Feb 16, 2001RXYes6,682,348<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ARESTIN

Country Document Number Estimated Expiration
Colombia5611079<disabled in preview>
Australia2009201777<disabled in preview>
Spain2427272<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc